Hemorrhoidectomy wound
Conditions
Interventions
Experimental group 1:After iodine debridement, apply sterile wound care ointment to the affected area at a thickness of about 3 mm and covered with gauze.
Experimental group 2:After iodine debridement, Recombinant Human Basic Fibroblast Growth Factor External Use (rh-bFGF) was evenly applied to the affected area and covered with gauze
Control group:Iodine debridement without any intervention
Sponsors
Yantai Yuhuangding Hostital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with hemorrhoids: confirmed to have hemorrhoids through clinical diagnosis, anorectal examination, etc. 2.Age within a certain range: 18-60 years old (usually the appropriate age range is determined according to the purpose of the experiment). 3.Symptoms are obvious: such as pain, bleeding, itching, prolapse, etc., to ensure that patients can benefit from the experiment. 4.Agree to participate in the experiment and sign the informed consent form: patients must participate voluntarily and understand the purpose, risks and benefits of the experiment. 5.Able to comply with the experimental plan: including timely debridement, medication, follow-up and other requirements. 6.No serious comorbidities: Try to choose patients with relatively stable conditions to reduce the impact of other factors on the experimental results. 7.No other treatments that may affect the experimental results: No other hemorrhoid drugs or treatments have been used within a certain period of time.
Exclusion criteria
Exclusion criteria: 1. Other anorectal diseases: such as anal fissures, anal fistulas, rectal polyps, etc., to avoid confounding the experimental results. 2. Patients with cardiovascular and cerebrovascular diseases, indigestion, autoimmune diseases, endocrine system diseases, liver and kidney dysfunction, and severe hematological diseases that may affect the safety or efficacy of the experiment. 3. Pregnant or lactating women: Usually excluded due to safety concerns for the fetus or infant. 4. Allergic constitution: Patients who are allergic to the experimental drugs or their components should be excluded. 5. Patients with a propensity for scarring: Those who could bias the experimental results should be excluded. Infected wounds: May affect the assessment of experimental results. 6. Recent hemorrhoid surgery or other related treatments: May affect the assessment of experimental results. 7. Patients with mental illnesses or those unable to cooperate with the experiment: May affect the accuracy and reliability of the data. 8. Currently participating in other clinical trials: To avoid the burden of multiple experiments on the patient and interference with experimental results. 9. Other situations deemed unsuitable by the researcher: Such as serious compliance issues or other special circumstances. 10.Other situations deemed unsuitable by the researcher: such as serious compliance issues or other special circumstances.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound size after hemorrhoidectomy; | — |
Countries
China
Contacts
Public ContactZaiqiu Wang
Yantai Yuhuangding Hospital
Outcome results
None listed